Related Experiment Video
Updated: May 22, 2026
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Construction and external validation of a prognostic model for high-grade glioma based on IDH1 mutation status:
Ping Lu1, Ruyuan Guo1, Guoli Zhao1
1Department of Radiotherapy, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University Taiyuan 030013, Shanxi, China.
Abstract:
This retrospective cohort study investigated the impact of isocitrate dehydrogenase 1 (IDH1) mutations on the efficacy and prognosis of concurrent chemoradiotherapy in high-grade gliomas (HGGs) and constructed a validated overall survival (OS) nomogram model. A total of 242 patients were included in the training cohort (2019-2021) and 182 patients in the time validation cohort (2022-2023). All patients received standard concurrent chemoradiotherapy. The median progression-free survival (PFS) in the 72 IDH1-mutant patients was 27.0 months, significantly longer than the 12.0 months in the 170 wild-type patients (hazard ratio =1.79; P<0.001). OS was also longer in IDH1-mutant patients (this endpoint has not yet been met), while the OS in wild-type patients was 20.0 months (HR=2.55; P<0.001). Furthermore, the objective response rate (ORR) in IDH1-mutant patients was 58.3%, significantly higher than the 37.6% in wildtype patients (P=0.005); the disease control rate was 88.9%, also higher than the 76.5% in wildtype patients (P=0.041). Cox regression analysis identified five independent prognostic factors associated with OS: IDH1 wildtype (HR=1.638), Karnofsky Performance Status (KPS) score <70 (HR=1.396), WHO grade 4 (HR=2.273), O6-methylguanine-DNA methyltransferase (MGMT) demethylation (HR=2.054), and <6 cycles of adjuvant chemotherapy (HR=1.977). The nomogram model constructed in this study showed good calibration, with a C-index of 0.721 in the training cohort and 0.640 in the time-validation cohort, demonstrating a positive net clinical benefit in both cohorts. IDH1 status showed significant interactions with adjuvant chemotherapy cycles (P=0.007) and MGMT methylation status (P=0.040), respectively. In conclusion, IDH1 mutation is an independent predictor of good treatment response and improved prognosis in patients with HGGs receiving concurrent chemoradiotherapy, and the validated nomogram can serve as a practical tool for individualized clinical decision-making.
